|7-甲基-5-(3-(哌嗪-1-基甲基)-1,2,4-恶二唑-5-基)-2-(4-(三氟甲氧基)苄基)异吲哚啉-1-酮|CsnPharm

CAS No.: 1092453-15-0

AZD-8529 Catalog No. CSN22354

Synonyms: AZD-8529

AZD-8529 is a potent, highly selective and orally bioavailable positive allosteric modulator of mGluR2, with an EC50 of 285 nM, and shows no positive allosteric modulator responses at 20-25 M on the mGluR1, 3, 4, 5, 6, 7, and 8 subtypes.

规格	价格	促销价格	库存	数量

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

加入购物车大规格询价

加入收藏

产品咨询

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

纯度 & 质量文件批次:

靶点选择性

生物活性

实验方案

技术信息

生物活性

描述AZD-8529 is a potent, highly selective and orally bioavailable positive allosteric modulator of mGluR2, with an EC50 of 285 nM, and shows no positive allosteric modulator responses at 20-25 M on the mGluR1, 3, 4, 5, 6, 7, and 8 subtypes.
临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT00921804	Schizophrenia	Phase 2	Completed	-	United States, California ... more >> Research Site Garden Grove, California, United States Research Site Glendale, California, United States United States, Maryland Research Site Rockville, Maryland, United States Collapse <<
NCT00985933	Healthy Memor... more >>y Impairment Collapse <<	Early Phase 1	Completed	-	United States, Connecticut ... more >> Research Site New Haven, Connecticut, United States Collapse <<
NCT00886756	Healthy	Phase 1	Completed	-	United Kingdom ... more >> Research Site London, United Kingdom Collapse <<

实验方案

计算器摩尔计算器总药量计算器工作液计算器
储存液制备
- 1 mg
- 5 mg
- 10 mg
- 1 mM
- 2.0514 mL
- 10.2570 mL
- 20.5139 mL
- 5 mM
- 0.4103 mL
- 2.0514 mL
- 4.1028 mL
- 10 mM
- 0.2051 mL
- 1.0257 mL
- 2.0514 mL

技术信息

CAS号	1092453-15-0	储存条件	粉末液体 -20°C:3-6 月 -80°C:12月
分子式	C24H24F3N5O3	运输	蓝冰
分子量	487.47	别名	AZD-8529

大规格询价

号为必填项

姓名: 邮箱: 手机号:

留言:

提交

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT00921804	Schizophrenia	Phase 2	Completed	-	United States, California ... more >> Research Site Garden Grove, California, United States Research Site Glendale, California, United States United States, Maryland Research Site Rockville, Maryland, United States Collapse <<
NCT00985933	Healthy Memor... more >>y Impairment Collapse <<	Early Phase 1	Completed	-	United States, Connecticut ... more >> Research Site New Haven, Connecticut, United States Collapse <<
NCT00886756	Healthy	Phase 1	Completed	-	United Kingdom ... more >> Research Site London, United Kingdom Collapse <<
NCT00755378	Healthy Volunteer	Phase 1	Completed	-	United States, Pennsylvania ... more >> Research Site Philadelphia, Pennsylvania, United States Collapse <<
NCT00986531	Schizophrenia	Phase 1	Completed	-	United States, Pennsylvania ... more >> Research Site Philadelphia, Pennsylvania, United States Collapse <<
NCT02401022	Tobacco Use Disorder	Phase 2	Completed	-	United States, California ... more >> Pharmacology Research Institute Encino, California, United States, 91316 Pacific Treatment and Research Center La Jolla, California, United States, 92037 Pharmacology Research Institute Los Alamitos, California, United States, 90720 Pharmacology Research Institute Newport Beach, California, United States, 92660 United States, Maryland University of Maryland - College Park College Park, Maryland, United States, 20742 United States, New York Columbia University Medical Center New York, New York, United States, 10019 United States, Ohio University of Cincinnati Cincinnati, Ohio, United States, 45229 United States, Pennsylvania Centers for the Studies of Addiction Philadelphia, Pennsylvania, United States, 19104 United States, Virginia Virginia Commonwelath University Richmond, Virginia, United States, 23219 Collapse <<
NCT02401022	-	-	Completed	-	-
NCT00765492	Healthy Volunteer	Phase 1	Completed	-	-

AZD-8529 Catalog No. CSN22354

靶点选择性

请登录您的专属账户

确认信息